IBDEI0PP ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11552,1,3,0)
 ;;=3^Hyperkalemia
 ;;^UTILITY(U,$J,358.3,11552,1,4,0)
 ;;=4^E87.5
 ;;^UTILITY(U,$J,358.3,11552,2)
 ;;=^60041
 ;;^UTILITY(U,$J,358.3,11553,0)
 ;;=E87.6^^46^559^20
 ;;^UTILITY(U,$J,358.3,11553,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11553,1,3,0)
 ;;=3^Hypokalemia
 ;;^UTILITY(U,$J,358.3,11553,1,4,0)
 ;;=4^E87.6
 ;;^UTILITY(U,$J,358.3,11553,2)
 ;;=^60610
 ;;^UTILITY(U,$J,358.3,11554,0)
 ;;=E87.8^^46^559^8
 ;;^UTILITY(U,$J,358.3,11554,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11554,1,3,0)
 ;;=3^Electrolyte & Fluid Balance Disorders NEC
 ;;^UTILITY(U,$J,358.3,11554,1,4,0)
 ;;=4^E87.8
 ;;^UTILITY(U,$J,358.3,11554,2)
 ;;=^5003026
 ;;^UTILITY(U,$J,358.3,11555,0)
 ;;=E26.81^^46^559^5
 ;;^UTILITY(U,$J,358.3,11555,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11555,1,3,0)
 ;;=3^Bartter's Syndrome
 ;;^UTILITY(U,$J,358.3,11555,1,4,0)
 ;;=4^E26.81
 ;;^UTILITY(U,$J,358.3,11555,2)
 ;;=^329906
 ;;^UTILITY(U,$J,358.3,11556,0)
 ;;=E23.2^^46^559^7
 ;;^UTILITY(U,$J,358.3,11556,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11556,1,3,0)
 ;;=3^Diabetes Insipidus
 ;;^UTILITY(U,$J,358.3,11556,1,4,0)
 ;;=4^E23.2
 ;;^UTILITY(U,$J,358.3,11556,2)
 ;;=^33572
 ;;^UTILITY(U,$J,358.3,11557,0)
 ;;=E83.41^^46^559^15
 ;;^UTILITY(U,$J,358.3,11557,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11557,1,3,0)
 ;;=3^Hypermagnesemia
 ;;^UTILITY(U,$J,358.3,11557,1,4,0)
 ;;=4^E83.41
 ;;^UTILITY(U,$J,358.3,11557,2)
 ;;=^5003002
 ;;^UTILITY(U,$J,358.3,11558,0)
 ;;=E21.3^^46^559^17
 ;;^UTILITY(U,$J,358.3,11558,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11558,1,3,0)
 ;;=3^Hyperparathyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,11558,1,4,0)
 ;;=4^E21.3
 ;;^UTILITY(U,$J,358.3,11558,2)
 ;;=^331438
 ;;^UTILITY(U,$J,358.3,11559,0)
 ;;=E83.42^^46^559^21
 ;;^UTILITY(U,$J,358.3,11559,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11559,1,3,0)
 ;;=3^Hypomagnesemia
 ;;^UTILITY(U,$J,358.3,11559,1,4,0)
 ;;=4^E83.42
 ;;^UTILITY(U,$J,358.3,11559,2)
 ;;=^5003003
 ;;^UTILITY(U,$J,358.3,11560,0)
 ;;=N25.1^^46^559^25
 ;;^UTILITY(U,$J,358.3,11560,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11560,1,3,0)
 ;;=3^Nephrogenic Diabetes Insipidus
 ;;^UTILITY(U,$J,358.3,11560,1,4,0)
 ;;=4^N25.1
 ;;^UTILITY(U,$J,358.3,11560,2)
 ;;=^5015616
 ;;^UTILITY(U,$J,358.3,11561,0)
 ;;=E27.49^^46^559^2
 ;;^UTILITY(U,$J,358.3,11561,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11561,1,3,0)
 ;;=3^Adrenocortical Insufficiency,Other
 ;;^UTILITY(U,$J,358.3,11561,1,4,0)
 ;;=4^E27.49
 ;;^UTILITY(U,$J,358.3,11561,2)
 ;;=^5002743
 ;;^UTILITY(U,$J,358.3,11562,0)
 ;;=E72.09^^46^559^4
 ;;^UTILITY(U,$J,358.3,11562,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11562,1,3,0)
 ;;=3^Amino-Acid Transport Disorders,Other
 ;;^UTILITY(U,$J,358.3,11562,1,4,0)
 ;;=4^E72.09
 ;;^UTILITY(U,$J,358.3,11562,2)
 ;;=^5002895
 ;;^UTILITY(U,$J,358.3,11563,0)
 ;;=N25.89^^46^559^23
 ;;^UTILITY(U,$J,358.3,11563,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11563,1,3,0)
 ;;=3^Impaired Renal Tubular Function Disorders,Other
 ;;^UTILITY(U,$J,358.3,11563,1,4,0)
 ;;=4^N25.89
 ;;^UTILITY(U,$J,358.3,11563,2)
 ;;=^5015618
 ;;^UTILITY(U,$J,358.3,11564,0)
 ;;=E26.89^^46^559^12
 ;;^UTILITY(U,$J,358.3,11564,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11564,1,3,0)
 ;;=3^Hyperaldosteronism,Other
 ;;^UTILITY(U,$J,358.3,11564,1,4,0)
 ;;=4^E26.89
 ;;^UTILITY(U,$J,358.3,11564,2)
 ;;=^5002737
 ;;^UTILITY(U,$J,358.3,11565,0)
 ;;=N25.81^^46^559^29
